Vipul C. Chitalia, MD, PhD
Boston University Chobanian & Avedisian School of Medicine

MD, Seth G.S. Medical College
MBBS, Lokmanya Tilak Medical College and Hospital
PhD, Boston University School of Medicine
DM, Seth G.S. Medical College

Our laboratory focuses on the role of post-translational modifications of proteins, especially polyubiquitnation of the key mediators of vascular pathologies in diseases such as cancer and renal failure. While these diseases are discrete, several fundamental biological processes remain similar. Through a highly collaborative network, our laboratory harnesses the power of various cellular and molecular biological tools, relevant animal models (zebrafish and mice), computational methods and machine-learning techniques and strives to validate these findings and hypotheses in humanized models or human samples from large data bases, which highlights the translational nature of our approach.

A. Vascular diseases in kidney failure: Close to 20 million Americans or 10% of US population suffer from the chronic kidney disease (CKD). Among plethora of cardiovascular manifestations, CKD patients are particularly at high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation) in CKD patients. This area of CKD management warrants urgent investigation due to lack of risk predictors and CKD-specific therapeutic targets.
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity, and hence called uremic solutes/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes, which inhibits the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding into the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis) and to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.
Thrombosis being a dynamic and the multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM and established a Thrombosis and Hemostasis ARC, which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis.

B. Angiogenesis: Angiogenesis, a process of generation of novel blood vessel is fundamental during the development and in various diseases such as cancer. Wnt signaling, a highly conserved oncogenic pathway is critical in angiogenesis. Beta catenin is the prime mediator of Wnt activation. Focusing on the ubiquitination and proteasomal degradation of beta catenin, our previous work had described Jade-1, as an E3 ligases of wild-type beta catenin. Our recent efforts have specifically focused on c-Cbl as an E3 ligase for the mutant beta catenin and for the transcriptionally active beta catenin in the nucleus. These two species of beta catenin, once considered resistant to degradation are effectively downregulated by c-Cbl. Thus, c-Cbl is a unique E3 ligase of tumorigenic beta catenin, which is involved in several cancers including colorectal cancer pathogenesis. Leveraging the cancer animal models and human cancer samples including machine learning based quantitative histology! techniques, our group investigates the colorectal cancer pathogenesis to gain deeper understanding of the role of E3 ligases of beta catenin E3 ligases in various cancers.

Boston University
Whitaker Cardiovascular Institute

Boston University
Evans Center for Interdisciplinary Biomedical Research

Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Disease-specific risk factors for thrombosis following vascular interventions
08/01/2023 - 07/31/2028 (PI)
National Heart, Lung, and Blood Institute/NIH/DHHS

Cancer-Associated Thromboembolism as Affected by Health Disparities (CAT-HD)
07/01/2021 - 06/30/2025 (PI)
Boston University School of Medicine American Heart Assoc

Mechanisms of drug-coated balloon therapy
09/01/2021 - 08/31/2024 (PI)
Trustees of Boston University, BUMC National Heart, Lung

Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients
07/01/2020 - 05/31/2024 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

The Boston University Kidney and Medical Engineering Program (BU-KIDMEP)
04/01/2021 - 02/29/2024 (Multi-PI)
PI: Vipul C. Chitalia, MD, PhD
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

Frequency domain shortwave infrared spectroscopy (FD-SWIRS) for volume status monitoring during hemodialysis in end stage kidney disease
03/01/2022 - 01/31/2024 (PI)
Trustees of Boston University,CRC National Institute o

Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) Study
04/01/2022 - 06/30/2023 (PI)
University of Pennsylvania National Institute o

Thrombotic complication of uremia: role of prothrombotic uremic solutes
03/01/2019 - 02/28/2021 (PI)
National Institutes of Health/DHHS/NIH

Role of thrombosis in Calciphylaxis
07/01/2019 - 06/30/2020 (PI)
The General Hospital Corporation / MGH American Society of

Role of c-Cbi in Colon Cancer
05/01/2019 - 04/30/2020 (PI)
National Cancer Institute/NIH/DHHS National Institutes

Showing 10 of 14 results. Show All Results


Yr Title Project-Sub Proj Pubs
2023 Disease-specific risk factors for thrombosis following vascular interventions 1R01HL166608-01A1
2023 Frequency domain shortwave infrared spectroscopy (FD-SWIRS) for volume status monitoring during hemodialysis in end stage kidney disease 5R21DK132784-02
2023 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 5R25DK128858-03
2022 Frequency domain shortwave infrared spectroscopy (FD-SWIRS) for volume status monitoring during hemodialysis in end stage kidney disease 1R21DK132784-01
2022 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 5R25DK128858-02
2021 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 1R25DK128858-01
2021 Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients 5R21DK119740-02
2020 Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients 1R21DK119740-01A1
2019 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-04 18
2018 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-03 18
Showing 10 of 22 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Smeds MR, Cheng TW, King E, Williams M, Farber A, Chitalia VC, Siracuse JJ. Characterization of long-term survival in Medicare patients undergoing arteriovenous hemodialysis access. J Vasc Surg. 2024 Jan 17.View Related Profiles. PMID: 38237702
  2. Lotfollahzadeh S, Yang X, Wu Wong DJ, Han J, Seta F, Ganguli S, Jose A, Ravid K, Chitalia VC. Venous Thrombosis Assay in a Mouse Model of Cancer. J Vis Exp. 2024 Jan 05; (203).View Related Profiles. PMID: 38251710
  3. Zhu M, Arinze N, Buitron de la Vega P, Alonso A, Levin S, Farber A, King E, Kobzeva-Herzog A, Chitalia VC, Siracuse JJ. High Prevalence of Adverse Social Determinants of Health in Dialysis Access Creation Patients in a Safety-Net Setting. Ann Vasc Surg. 2024 Mar; 100:31-38.View Related Profiles. PMID: 38110081
  4. Lin W, Mousavi F, Blum BC, Heckendorf CF, Moore J, Lampl N, McComb M, Kotelnikov S, Yin W, Rabhi N, Layne MD, Kozakov D, Chitalia VC, Emili A. Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease. Front Pharmacol. 2023; 14:1243505.View Related Profiles. PMID: 38089059; PMCID: PMC10715419; DOI: 10.3389/fphar.2023.1243505;
  5. Levin SR, Alonso A, Salazar ED, Farber A, Chitalia VC, King EG, Cheng TW, Siracuse JJ. Recent evaluation by nephrologists is associated with decreased incidence of tunneled dialysis catheter being used at the time of first arteriovenous access creation. J Vasc Surg. 2024 Jan; 79(1):128-135.View Related Profiles. PMID: 37742733
  6. Belghasem M, Yin W, Lotfollahzadeh S, Yang X, Meyer RD, Napoleon MA, Sellinger IE, Vazirani A, Metrikova E, Jose A, Zhebrun A, Whelan SA, Lee N, Rahimi N, Chitalia VC. Tryptophan Metabolites Target Transmembrane and Immunoglobulin Domain-Containing 1 Signaling to Augment Renal Tubular Injury. Am J Pathol. 2023 Oct; 193(10):1501-1516.View Related Profiles. PMID: 37676196; PMCID: PMC10548275; DOI: 10.1016/j.ajpath.2023.06.018;
  7. Idrees N, Haroon S, Zhang Y, Mangio JC, Siracuse JJ, Francis JM, Ganguli S, Daly K, Diamond M, Vilvendhan R, Cabral H, Dember LM, Farber A, Kolachalama VB, Chitalia VC. Contrast Venography Versus Intravenous Ultrasound in Hemodialysis Arteriovenous Access Dysfunction. Kidney Int Rep. 2023 Sep; 8(9):1887-1891.View Related Profiles. PMID: 37705907; PMCID: PMC10496077; DOI: 10.1016/j.ekir.2023.06.013;
  8. Budbazar E, Sulser Ponce De Leon S, Tsukahara Y, Liu H, Huangfu Y, Wang Y, Seabra PM, Yang X, Goodman JB, Wan X, Chitalia V, Han J, Seta F. Redox Dysregulation of Vascular Smooth Muscle Sirtuin-1 in Thoracic Aortic Aneurysm in Marfan Syndrome. Arterioscler Thromb Vasc Biol. 2023 Aug; 43(8):e339-e357.View Related Profiles. PMID: 37288573; PMCID: PMC10524979; DOI: 10.1161/ATVBAHA.123.319145;
  9. Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H, Elbers DC, Do NV, Brophy MT, Gaziano JM, Lotfollahzadeh S, Chitalia V, Ravid K, Fillmore NR. Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open. 2023 Jun 01; 6(6):e2317945.View Related Profiles. PMID: 37306999; PMCID: PMC10261992; DOI: 10.1001/jamanetworkopen.2023.17945;
  10. Lotfollahzadeh S, Xia C, Amraei R, Hua N, Kandror KV, Farmer SR, Wei W, Costello CE, Chitalia V, Rahimi N. Inactivation of Minar2 in mice hyperactivates mTOR signaling and results in obesity. Mol Metab. 2023 Jul; 73:101744.View Related Profiles. PMID: 37245847; PMCID: PMC10267597; DOI: 10.1016/j.molmet.2023.101744;
Showing 10 of 112 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 105 publications over 23 distinct years, with a maximum of 14 publications in 2023


2019 Department of Medicine, and School of Medicine, Boston University: Robert Dawson Evans Research Mentoring Award
2017 Boston University School of Medicine : Evan’s Junior Faculty Merit Award
2016 Boston University : Outstanding Mentor award for UROP mentoring
2015-2017 Boston University School of Medicine: Evan’s Junior Faculty Merit Award
2007 Boston University School of Medicine: Annual Evan’s Research Day award
2005 Boston University School of Medicine: Annual Evan’s Research Day award
1998-1999 International Society of Nephrology: International Society of Nephrology Fellowship award
1995 University of Bombay: Gold medal Postdoctoral examination in Nephrology
1990-1992 University of Bombay: Merit Scholarship, Government of India
1987 University of Bombay: Charles Moorhead Prize
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Chronic Kidney Disease
E3 Ubiquitin Ligase
Uremic Vascular Disease
Wnt Signaling

I am an Assistant Professor of Medicine at Boston University School of Medicine and an affiliate of Biomedical Engineering at Harvard-MIT Division of Science and Technology, MIT. I am also an attending nephrologist covering renal consults and dialysis and kidney transplant in-patients services at Boston Medical Center. Teaching is my passion and I consider it as my honor to be able to contribute in the training of next generation of physicians, scientists and physician-scientists. I strongly believe that a true mentor is one who inspires passion from within and empowers a mentee to find his or her own path of success. Spanning over entire spectrum, our laboratory has trained several undergraduate students, graduate students and post doctoral fellows, of which several are clinical fellows from renal, cardiovascular and hematology-oncology specialties. Our laboratory has not only US researchers, but has students and post doctoral fellows from Europe, Middle East and Asia creating a truly international learning environment. I have been awarded 2016 Outstanding Mentor Award from the undergraduate research opportunity program (UROP) of Boston University and been nominated for best research mentoring award at BUSM.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Chitalia's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department